Under Armour is a popular brand among athletes and active people. The company tried to expand too quickly and has paid a price for it. Can it stage a come back? Read More
Scott Chan moved from China to the U.S. with family at the age of ten. He passed the rigorous entrance exam and attended the merit-based Stuyvesant High School, widely held to be best public school in New York City. He earned undergraduate degrees from New York University followed by an MBA degree from the Zicklin School of Business at Baruch College.
Shortly thereafter Scott partnered with Dr. Stephen Leeb on numerous financial publications. Today, he serves as the lead analyst for Real World Investing and The Complete Investor.
Mr. Chan is an avid baseball fan and enjoys outdoor activities in his spare time. A multicultural person, he reads Chinese and speaks fluent Mandarin and Cantonese Chinese.
Analyst Articles
Gilead has seen its stock price slide in recent years as sales of its hepatitis c drugs are falling sharply. Are better days ahead? Read More
BioPharmX is a penny stock that literally sells for pennies a share. However, a low price alone doesn't mean it's a compelling investment. Let's see if this biotech is a good buy for 2019. Read More
Verizon is one of those stocks that won't excite many people. Yet for conservative investors, the stock is as steady as they come. Read More
In Part 2 of our discussion on annuities, we touch on variable annuities and review the choices available to investors when an annuity begins to pay out. Read More
Annuities are insurance products that pay out income. They're a popular choice for conservative investors seeking a steady income stream. Read More
Money market funds are a way to invest cash in low-risk instruments while earning interest without locking up your cash like a CD. Read More
Celgene stock has been driven down to very low levels after a couple of pipeline disappointments in the past year. Is it a bargain or a value trap? Read More
Rexahn Pharmaceuticals is a tiny biotech company seeking to develop several cancer drugs. With the stock price near $1, is it worth taking a swing at? Read More
Cisco was at one time the most-valuable public company in the world by market cap. Today it is a mature company seeking to rejuvenate growth. Read More